Navigation Links
Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development

-- Part of larger effort to develop and distribute high-quality experimental tools that will speed progress toward better treatments for PD --

NEW YORK, March 23 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation announced that monoclonal LRRK2 antibodies, for use in understanding LRRK2 function and developing LRRK2-based therapeutics, will be available to Parkinson's researchers in academic/nonprofit and industry labs. In mid-April, the antibodies will be available free of charge to the entire PD research community for experimental use. This will allow researchers to undertake large-scale testing of the antibodies and provide feedback on their performance directly to MJFF. Once the best-performing antibodies have been identified, the Foundation will determine a practical distribution mechanism to make them available to the research community going forward.

"Our mission is to accelerate next-generation Parkinson's therapies on their path toward the clinic, and it is impossible to overstate access to high-quality, reliable experimental tools as a critical element of this push," said Katie Hood, CEO. "One of our top priorities is to mobilize financial and intellectual leadership around the creation of research tools and get them into scientists' hands to keep promising therapeutic strategies moving forward full-speed ahead."

The Foundation's ongoing investment in critical research tools is made possible through the generous support of The Brin Wojcicki Foundation.

About LRRK2 and LRRK2 Antibodies

LRRK2 is a Parkinson's-implicated gene discovered in 2004 that is now believed to be the single greatest genetic contributor to the disease. While it is the focus of intensive research in the Parkinson's field, a major roadblock to the successful development of LRRK2-based therapies is the lack of high-quality LRRK2 antibodies. Antibodies are used by researchers to identify where proteins can be found in the body, how they behave in cells, and how to manipulate their activity. Despite numerous attempts by individual researchers, high-quality LRRK2 antibodies are rare and often difficult for labs to obtain.

In 2009 MJFF convened a LRRK2 Antibodies Working Group composed of academic and industry researchers with specific expertise in LRRK2. At the recommendation of this group, MJFF engaged a company specializing in antibody development, Epitomics, Inc., to generate several highly sensitive and specific LRRK2 antibodies in large amounts.

The LRRK2 antibodies project is part of MJFF's broadly integrated strategy to drive LRRK2 research at every stage of drug development and accelerate the path of LRRK2-based drugs to the clinic.

How to Obtain Antibodies

For detailed scientific information on the LRRK2 antibodies and information on how to obtain them, researchers should visit PD Online Research ( or the new Research Tools page located on the Foundation's Web site (

Next Focus Area under MJFF's Research Tools Effort: Pre-clinical Models

In addition to the antibodies announced today, the Foundation is working to develop and create distribution channels for new pre-clinical models of Parkinson's that better mimic the human condition. Multiple strains of new models are expected to come online for distribution over the course of 2010. There is an urgent need for such models, particularly for the development of treatments that could slow or stop the progression of PD (something no current treatment has been conclusively proven to do). The Michael J. Fox Foundation has been a field leader in the development of PD models for several years, with investments totaling approximately $13 million to date.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $175 million in research to date. 

SOURCE Michael J. Fox Foundation

Back to top



SOURCE Michael J. Fox Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
2. Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant
3. Oxford BioTherapeutics Appoints Michael Moore as Chairman
4. The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinsons Disease Treatments
5. Double Helix Consulting Enhances its Strategic Product Commercialization Services with Appointment of Michael Rizzo as Vice President
6. Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research
7. Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section
8. BioStorage Technologies, Inc., Welcomes Catherine Michael as Global Head of Sample Management Operations
9. Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
10. Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer of Global Bioanalytical Services
11. Statement From Michael Hansen, CEO of Elseviers Health Sciences Division, Regarding Australia Based Sponsored Journal Practices Between 2000 and 2005
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , November 26, 2015 ... Biobanking Market 2016 - 2020 report analyzes that ... integrity and quality in long-term samples, minimizing manual ... cost-effectiveness. Automation minimizes manual errors such as mislabeling ... efficiency. Further, it plays a vital role in ...
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015 Paris , ... --> Paris , qui s,est tenu ... le leader de l,innovation biométrique, a inventé le premier ... empreintes sur la même surface de balayage. Jusqu,ici, deux ... pour les empreintes digitales. Désormais, un seul scanner est ...
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
Breaking Biology News(10 mins):